Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

Inclusion Criteria: * Participant must have kidney failure and must have been on stable intermittent HD for at least 3 months prior to screening. * Participant must be stable on a concomitant medication and/or treatment regimen (defined as not starting a new treatment/medication\[s\] or a change in the dosage or frequency of the concomitant medication\[s\] within at least 4 weeks prior to screening). * Participants with controlled T2DM may be included, if they have: (a) HbA1c ≤ 10% at screening. * Body weight ≥ 50 kg and BMI within the range 18 to 40 kg/m2, inclusive, as measured at screening. * All female participants must have a negative serum pregnancy test at screening and all females of child-bearing potential must have a negative serum pregnancy test on Periods 1 and 2 Day -1 and must not be lactating (confirmed at screening). Females must also fulfil one of the following criteria: Females not of child-bearing potential, defined as females who are either permanently sterilised (hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation) or who are post-menopausal; OR Females of child-bearing potential who are sexually active with a nonsterilised male must use one highly effective method of birth control from enrolment throughout the study and until at least 4 weeks after the last dose of study intervention * Capable of giving signed informed consent * Provision of signed and dated written Optional Genomics Initiative Research Information and…